IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 22,805 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 22,805 shares of the stock in a transaction on Tuesday, March 17th. The stock was purchased at an average cost of $1.31 per share, with a total value of $29,874.55. Following the acquisition, the insider owned 1,157,363 shares in the company, valued at approximately $1,516,145.53. This represents a 2.01% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Trading Up 2.2%

IRIDEX stock opened at $0.90 on Friday. The stock has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.95. IRIDEX Corporation has a 12 month low of $0.61 and a 12 month high of $1.65. The company has a market capitalization of $15.78 million, a PE ratio of -4.49 and a beta of 0.67.

IRIDEX (NASDAQ:IRIX) last released its quarterly earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. As a group, analysts predict that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Institutional Trading of IRIDEX

Institutional investors have recently added to or reduced their stakes in the stock. United Capital Financial Advisors LLC acquired a new stake in IRIDEX during the 2nd quarter valued at approximately $41,000. Weber Capital Management LLC ADV acquired a new position in shares of IRIDEX in the 2nd quarter worth approximately $206,616. Diversify Advisory Services LLC acquired a new position in shares of IRIDEX in the 2nd quarter worth approximately $30,000. Bank of New York Mellon Corp bought a new stake in shares of IRIDEX in the 2nd quarter valued at $29,000. Finally, Renaissance Technologies LLC boosted its stake in shares of IRIDEX by 6.7% in the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 25,067 shares during the last quarter. 20.10% of the stock is currently owned by institutional investors.

Key IRIDEX News

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $3.00.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.